Back to top
more

Ginkgo Bioworks (DNA)

(Delayed Data from NYSE)

$13.46 USD

13.46
1,452,247

-0.50 (-3.58%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $13.47 +0.01 (0.07%) 4:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $13.96, signifying a -6.31% move from its prior day's close.

Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $9.6, signifying a +1.8% move from its prior day's close.

Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $10.79, denoting a -2.53% move from the preceding trading day.

Zacks Equity Research

Ginkgo Bioworks (DNA) Soars 18.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Ginkgo Bioworks (DNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Moves 1.41%: What You Should Know

by Zacks Equity Research

The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $9.32, representing a +1.41% change from its previous close.

Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ginkgo Bioworks (DNA) delivered earnings and revenue surprises of -28.46% and 17.12%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 13.89% and 11.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $7.37, representing a -0.14% change from its previous close.

Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) Rises Yet Lags Behind Market: Some Facts Worth Knowing

by Zacks Equity Research

In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.60, marking a +0.8% move from the previous day.

Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Moves -1.94%: What You Should Know

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $8.09, signifying a -1.94% move from its prior day's close.

Zacks Equity Research

Wall Street Analysts Think Ginkgo Bioworks (DNA) Could Surge 41.59%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Ginkgo Bioworks (DNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Here's Why Ginkgo Bioworks (DNA) is Poised for a Turnaround After Losing -28.84% in 4 Weeks

by Zacks Equity Research

The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $6.59, denoting a -0.9% change from the preceding trading day.

Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $7.27, moving +1.39% from the previous trading session.

Zacks Equity Research

After Plunging -52.33% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why

by Zacks Equity Research

Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ginkgo Bioworks (DNA) delivered earnings and revenue surprises of -25.52% and 2.74%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $12.32, moving -0.48% from the previous trading session.

Zacks Equity Research

Strength Seen in Ginkgo Bioworks (DNA): Can Its 14.5% Jump Turn into More Strength?

by Zacks Equity Research

Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Regeneron (REGN) delivered earnings and revenue surprises of 3.87% and 0.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Moves -0.24%: What You Should Know

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.25 in the latest trading session, marking a -0.24% move from the prior day.

Zacks Equity Research

Ginkgo Bioworks (DNA) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Ginkgo Bioworks (DNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how BioLife Solutions, Inc. (BLFS) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year.

Zacks Equity Research

NeoGenomics (NEO) Surges 9.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

NeoGenomics (NEO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ALX Oncology Holdings Inc. (ALXO) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year.